All In Biotech

Drug Trial Radar · NCT06770439

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Apr 18, 2025

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase II study to evaluate the safety, tolerability and efficacy of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer, including Part1 (safe lead-in phase) and Part2 (extension phase). In part1, patients with CLDN18.2-positive advanced pancreatic adenocarcinoma who had or had not previously received systemic therapy were treated with chemotherapy in IBI343 with AG regimen (albumin paclitaxel with gemcitabine). In part2, 40 patients with CLDN18.2-positive advanced PDAC will be enrolled, 1:1 randomized to Arm A and Arm B, respectively. In Arm A, patients will receive IBI343 TBD + gemcitabine TBD + albumin-bound paclitaxel TBD; and in Arm B, patients will receive gemcitabine 1000mg / m2 d1, d8 Q3W + albumin-bound paclitaxel 125mg / m2d1, d8 Q3W treatment.

Conditions

  • Advanced Pancreatic Cancers

Interventions

  • IBI343Drug

    IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate

  • Gemcitabine+Albumin-bound paclitaxelDrug

    Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Up to 2 years
  2. Adverse EventTime frame: Up to 2 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Zhejiang University Schlool of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

  • the First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.